Previous studies have shown that FAB-M5 patients lose expression of the primitive marker CD117 and up-regulate the expression of the monocytic marker CD11b [32] and monocytic subclones confer resistance to venetoclax-based therapy in AML patients [33]. This evidence concerns the gene KIT and acute myeloid leukemia.